



RECEIVED

JAN 28 2003

TECH CENTER 1600/2900

Atty. Docket No.: 8654/2072

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Krissansen, et al.
Serial No.: 10/014,887
Filed: December 11, 2001
Entitled: "Cancer Therapy"

Examiner: Not Yet Assigned

Group Art Unit: 1615

Conf. No.: 2382

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231.

David J. Dykeman

Name of Person Mailing Paper

Signature of Person Mailing Paper

Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL LETTER

Enclosed for filing in the above-identified patent application, please find the following documents:

1. Supplemental Information Disclosure Statement;
2. Form PTO-1449 citing 124 references;
3. Copies of 124 cited references; and
4. Return Post Card.

The Commissioner for Patents is hereby authorized to charge any additional fees or credit any overpayment in the total fees to Deposit Account No. 16-0085, Reference No. 8654/2072. A duplicate of this transmittal letter is enclosed for this purpose.

Respectfully submitted,

Date: January 22, 2003

Name: David J. Dykeman
Registration No.: 46,678
Customer No.: 29933
Palmer & Dodge LLP
111 Huntington Avenue
Boston, MA 02199-7613
Tel: 617-239-0100

BEST AVAILABLE COPY

**RECEIVED**

JAN 28 2003

TECH CENTER 1600/2900

Atty. Docket No.: 8654/2072

PATENT**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Krissansen, et al.
Serial No.: 10/014,887
Filed: December 11, 2001
Entitled: "Cancer Therapy"

Examiner: Not Yet Assigned

Group Art Unit: 1615

Conf. No.: 2382

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231.

David J. Dykeman

Name of Person Mailing Paper

Signature of Person Mailing Paper

Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.56, 1.97 AND 1.98

Dear Sir:

In accordance with the duty of disclosure under 37 CFR § 1.56, Applicant submits this Supplemental Information Disclosure Statement pursuant to 37 CFR §§ 1.97 and 1.98 in the above-identified application for consideration by the Patent Office. A listing of the cited documents is also enclosed, as well as, for the Examiner's convenience, copies of the documents in the list. Pursuant to CFR § 1.97(b)(3), because this Statement is being submitted before the first Office Action on the merits, no fee is required.

Applicant does not intend to represent that any of the documents submitted herein are material prior art to this invention or that the list represents an exhaustive search of documents related to this invention.

Applicant respectfully requests that the documents submitted herein be considered and made of record in this application.

Date: January 22, 2003

Respectfully submitted,

Name: David J. Dykeman

Registration No.: 46,678

Customer No.: 29933

Palmer & Dodge LLP

111 Huntington Avenue

Boston, MA 02199-7613

Tel: 617-239-0100

RECEIVED

JAN 28 2003

Page 1 of 15

USPTO Form 1449
Patent and Trademark Office

U.S. Department of Commerce

TECH CENTER 1600/2900

Attorney Docket No.

8654/2072

Serial No.

10/014,887

SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT

Applicant(s): Krissansen, et al.

Filing Date: December 11, 2001

Group: 1615

U.S. PATENT DOCUMENTS

Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
	1.	5,817,684	Oct. 6, 1998	Fleisch, et al.	514	381	
	2.	5,910,505	Jun. 8, 1999	Fleisch, et al.	514	381	
	3.	5,281,620	Jan. 25, 1994	Denny, et al.	514	455	

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Publication Date	Country	Class	Subclass	Translation	
							YES	NO
	4.	EP 0 743 064	20 Nov. 1996	European	A61K	31/19		
	5.	WO 94/23753	27 Oct. 1994	PCT	A61K	47/48		
	6.	WO 95/09621	13 April 1995	PCT	A61K	31/195		
	7.	WO 97/34482	23 Sept. 1997	PCT	A01N	43/00		
	8.	WO 98/25600	18 June 1988	PCT	A61K	31/19		
	9.	WO 98/42335	1 Oct. 1998	PCT	A61K	31/41		

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

	10.	Wilson, W., Baguley B.; "Combination of the Antivascular Agent DMXAA with Radiation and Chemotherapy", <u>International Journal of Oncology, Biology and Physics</u> , volume 46, number 3, February 1, 2000, abstract 46, page 706.
	11.	Rustin, G.; "Vascular Targeting in the Clinic"; Abstract; <u>ICTR 2000: 1st Int'l Conference on Translational Research A.</u> , 2000.
	12.	Baguley, B.C. et al; "291 mechanisms of Tumor Blood Flow Inhibition by The Antitumour Drug DMXAA (5,6-dimethylxanthenone-4-acetic acid"; <u>Proceedings of the 11th NCI EORTC AACR Symposium; Copyright © 2000 Stichting NCI-EORTC Symposium on new drugs in cancer therapy; publ. By the AACR; Published as a Supplement to Clinical Cancer Research, vol 6, November 2000.</u>
	13.	Chaplin, D.J., et al; "Antivascular approaches to solid tumor therapy; evaluation of tubulin binding agents"; <u>Proc. Annu. Meet. Am. Assoc. Cancer Res.</u> , March 1996, vol 37, #3009: 440-441 and Abstract.
	14.	Hornung R. L., et al; "Augmentation of Natural Killer Activity, Induction of IFN and Development Tumor Immunity During the Successful Treatment of Established Murine Renal Cancer Using Flavone Acetic Acid and IL-2"; <u>The Journal of Immunology</u> (1988) vol 141(10), pages 3671-3679.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

**Copies of references not provided at the time of this submission.

**RECEIVED**

JAN 28 2003


U.S. Department of Commerce Patent and Trademark Office TECH CENTER 1600/2900 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				Attorney Docket No. 8654/2072		Serial No. 10/014,887		
				Applicant(s): Krissansen, et al.				
				Filing Date: December 11, 2001		Group: 1615		
U.S. PATENT DOCUMENTS								
Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)	
	121.	5,914,340	June 22, 1999	Fleisch et al.	514	381	March 13, 1998	
	122.	5,977,077	November 2, 1999	Winter et al.	514	23	March 20, 1996	
FOREIGN PATENT DOCUMENTS								
Examiner Initial		Document No.	Publication Date	Country	Class	Subclass	Translation	
							YES	NO
	15.	WO 98/42332	1 Oct. 1998	PCT	A61K	31/35		
	16.	WO 98/42336	1 Oct. 1998	PCT	A61K	31/52		
	17.	WO 98/42337	1 Oct. 1998	PCT	A61K	31/41		
	18.	WO 98/42346	1 Oct. 1998	PCT	A61K	31/52		
	19.	WO 98/42650	1 Oct. 1998	PCT	C07C	63/04		
	20.	WO 00/10600 A2	2 March 2000	PCT	A61K	39/00		
	21.	WO 00/10600 A3	2 March 2000	PCT	A61K	39/00		
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)								
	22.	Thomsen, L.L., et al.; "Nitric Oxide Production in endotoxin-resistant C3H/HeJ mice stimulated with flavone-8-acetic acid and xanthenone-4-acetic acid analogues"; <u>Biochem. Pharmacol.</u> , 43(11); pages 2401-2406; 1992.						
	23.	Lash, C.J., et al.; "Enhancement of the anti-tumor effects of the antivasular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs"; <u>Br. J. Cancer</u> , 78(4), pages 439-445, 1998.						
	24.	Pedley, R.B., et al.; "Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivasular agent"; <u>Cancer Res.</u> , 59(16), pages 3998-4003, August 15, 1999.						
	25.	Pruijn, F.B., et al.; "Mechanisms of enhancement of the antitumor activity of melphalan by the tumor blood flow inhibitor 5, 6-dimethylxanthenone-4-acetic acid"; <u>Cancer Chemother. Pharmacol.</u> , 39(6), pages 541-546, 1997.						
	26.	Rewcastle, et al.; "Potential Antitumor Agents. 58. Synthesis and Structure-Activity Relationships of Substituted Xanthenone-4-acetic Acids Active against the Colon 38 Tumor in Vivo"; <u>J. Med. Chem.</u> 32(4), pages 793-799, 1989.						
EXAMINER					DATE CONSIDERED			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant. **Copies of references not provided at the time of this submission.								



RECEIVED

JAN 28 2003

USPTO Form 1449 Patent and Trademark Office		TECH CENTER 1600/2900		Attorney Docket No. 8654/2072		Serial No. 10/014,887		
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				Applicant(s): Krissansen, et al.				
				Filing Date: December 11, 2001		Group: 1615		
U.S. PATENT DOCUMENTS								
Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)	
	123.	5,998,454	December 7, 1999	Fleisch et al.	514	381	March 13, 1998	
	124.	U.S. Patent Application Publication No. 2001/0027210	October 4, 2001	Wilson	514	455	January 31, 2001	
FOREIGN PATENT DOCUMENTS								
Examiner Initial		Document No.	Publication Date	Country	Class	Subclass	Translation	
							YES	NO
	27.	WO 00/16798	30 March 2000	PCT	A61K	38/28		
	28.	WO 01/34135 A2	17 May 2001	PCT	A61K	31/00		
	29.	WO 01/34137 A2	17 May 2001	PCT	A61K	31/00		
	30.	WO 01/34197 A2	17 May 2001	PCT	A61K	41/00		
	31.	WO 01/34198 A2	17 May 2001	PCT	A61K	41/00		
	32.	WO 02/09700 A1	7 Feb. 2002	PCT	A61K	31/352		
	33.	WO 00/48591	24 Aug. 2000	PCT	A61K	31/198		
	34.	EP 0 584 001 A1	29 July 1993	European	A61K	31/335		
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)								
	35.	Cliffe, S., et al.; "Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5, 6-dimethylxanthenone acetic acid"; <u>Int. J. Radiation Oncology Biol. Phys.</u> , 29(2), pages 373-377, 1994.						
	36.	Phillips, R.M. "Inhibition of DT-diaphorase (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) by 5, 6-dimethylxanthenone-4-acetic acid (DMXAA) and flavone-8-acetic acid (FAA): implications for bioreductive drug development"; <u>Biochem. Pharmacol.</u> , 58(2), pages 303-310, 1999.						
	37.	Ching, L.-M., et al.; "Effect of thalidomide on tumor necrosis factor production and anti-tumor activity induced by 5, 6-dimethylxanthenone-4-acetic acid"; <u>Br. J. Cancer</u> , 72(2), pages 339-343, 1995.						
	38.	Browne, W.L., et al.; "Suppression of serum tumor necrosis factor- α by thalidomide does not lead to reversal of tumor vascular collapse and anti-tumor activity of 5, 6-dimethylxanthenone-4-acetic acid"; <u>Anticancer Res.</u> , 18(6A), pages 4409-4414, 1998.						
EXAMINER					DATE CONSIDERED			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.								
**Copies of references not provided at the time of this submission.								

**RECEIVED**

JAN 28 2003

Page 4 of 15

TECH CENTER 1600/2900

USPTO Form 1449 U.S. Department of Commerce Patent and Trademark Office SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				Attorney Docket No. 8654/2072		Serial No. 10/014,887		
				Applicant(s): Krissansen, et al.				
				Filing Date: December 11, 2001		Group: 1615		
U.S. PATENT DOCUMENTS								
Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)	
FOREIGN PATENT DOCUMENTS								
Examiner Initial		Document No.	Publication Date	Country	Class	Subclass	Translation	
							YES	NO
	39.	EP 0 584 001 B1	14 May 1997	European	A61K	31/335		
	40.	JP 001247459	11 Sept. 2001	Japan	A61K	31/352		
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)								
	41.	Ching, L.M., et al.; "Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the antitumor agent 5, 6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumor necrosis factor-alpha and enhancement of antitumour activity"; <u>Br. J. Cancer</u> , 78(3), pages 336-343, 1998.						
	42.	Kestell, P., et al.; "Modulation of the pharmacokinetics of the antitumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice by thalidomide"; <u>Cancer Chemother. Pharmacol.</u> , 46(2), pages 135-141, 2000.						
	43.	Cao, Z., et al.; "Thalidomide increases both intra-tumoural tumor necrosis factor-alpha production and anti-tumor activity in response to 5, 6-dimethylxanthenone-4-acetic acid"; <u>Br. J. Cancer</u> , 80(5/6), pages 716-723, 1999.						
	44.	Baguley, B.C., et al.; "Serotonin involvement in the antitumour and host effects of flavone-8-acetic acid and 5, 6-dimethylxanthenone-4-acetic acid"; <u>Cancer Chemother. Pharmacol.</u> , 33(1), pages 77-81, 1993.						
	45.	Zwi, L.J., et al.; "Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents"; <u>Oncol. Res.</u> , 6(2), pages 79-85, 1994.						
	46.	Zhao, L., et al.; "Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetics of 5, 6-dimethylxanthenone-4-acetic acid (DMXAA)"; <u>Cancer Chemother. Pharmacol.</u> , 47(6), pages 491-497, 2001.						
	47.	Futami, H., et al.; "Cytokine induction and therapeutic synergy with interleukin-2 against murine renal and colon cancers by xanthenone-4-acetic acid derivatives"; <u>J. Immunother.</u> , 12(4), pages 247-255, 1992.						
EXAMINER					DATE CONSIDERED			
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.</small>								
<small>**Copies of references not provided at the time of this submission.</small>								

**RECEIVED**

JAN 28 2003

TECH CENTER 1600/2900


USPTO Form 1449 U.S. Department of Commerce Patent and Trademark Office				Attorney Docket No. 8654/2072		Serial No. 10/014,887	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				Applicant(s): Krissansen, et al.			
				Filing Date: December 11, 2001		Group: 1615	
U.S. PATENT DOCUMENTS							
Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
FOREIGN PATENT DOCUMENTS							
Examiner Initial		Document No.	Publication Date	Country	Class	Subclass	Translation YES NO
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)							
	48.	Ching, L.M., et al.; "Interaction between endotoxin and the antitumour agent 5, 6-dimethylxanthene-4-acetic acid in the induction of tumor necrosis factor and haemorrhagic necrosis of colon 38 tumors"; <u>Cancer Chemother. Pharmacol.</u> , 35(2), pages 153-160, 1994.					
	49.	Ching, L.M., et al.; "Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5, 6-dimethylxanthene-4-acetic acid (DMXAA) in TNF knockout mice"; <u>Cancer Res.</u> , 59(14), pages 3304-3307, 1999.					
	50.	Thomsen, L.L., et al.; "Tumor-dependent increased plasma nitrate concentrations as an indication of the antitumor effect of flavone-8-acetic acid and analogues in mice"; <u>Cancer Res.</u> , 51(1), pages 77-81, 1991.					
	51.	Baguley, et al.; "Evidence that the 5-hydroxytryptamine antagonist, cyproheptadine, modulates nitric oxide production in mice in response to flavone acetic acid, vinblastine and other agents"; <u>Biol. Nitric Oxide, Proc. Int. Meet.</u> ; Meeting Date 1991, Volume 2, (1992); 222-224, 1991.					
	52.	Kanwar, J.R., et al.; "Taking lessons from dendritic cells: Multiple xenogeneic ligands for leukocyte integrins have the potential to stimulate anti-tumor immunity"; <u>Gene Therapy</u> , 6: pages 1835-1844, 1999.					
	53.	Kanwar, J.R., et al.; "Vascular attack by 5, 6-dimethylxanthene-4-acetic acid combined with B7.1-mediated immunotherapy overcomes immune-resistance and leads to the eradication of large tumors"; <u>Cancer Res.</u> , 61(5), pages 1948-1956, 2001.					
	54.	Fujii H, et al, "Vaccination with B7-18 tumor and anti-adhesion therapy with RGD pseudo-peptide (FC-336) efficiently induce anti-metastatic effect"; <u>Clinical & Experimental Metastasis</u> , volume 16, pages 141-148, 1998.					
EXAMINER					DATE CONSIDERED		
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							
**Copies of references not provided at the time of this submission.							

**RECEIVED**

JAN 28 2003

TECH CENTER 1600/2900

USPTO Form 1449 U.S. Department of Commerce Patent and Trademark Office				Attorney Docket No. 8654/2072		Serial No. 10/014,887	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				Applicant(s): Krissansen, et al.			
				Filing Date: December 11, 2001		Group: 1615	
U.S. PATENT DOCUMENTS							
Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
FOREIGN PATENT DOCUMENTS							
Examiner Initial		Document No.	Publication Date	Country	Class	Subclass	Translation YES NO
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)							
	55.	Zitvogel L., et al.; "Interleukin-12 and b7.1 co-stimulation co-operate in the induction of effective antitumor immunity and therapy of established tumor"; <u>Eur. J. Immunol.</u> (1996), volume 26, pages 1335-1341.					
	56.	Lissoni P., et al, "Neuroimmunotherapy of advanced solid neoplasms with single evening subcutaneous injection of low-dose interleukin-2 and melatonin Preliminary results"; <u>European Journal of Cancer</u> , (1993), volume 29A(2), pages 185-189.					
	57.	Nawrocki S., and Mackiewicz A., "Genetically modified tumor vaccines-where we are today"; <u>Cancer Treatment Reviews</u> , (1999), volume 25, pages 29-46.					
	58.	Thrash-Bingham C. A., and Tartof K. D.; "aHIF: A natural antisense transcript overexpressed in human renal cancer during hypoxia"; <u>The Journal of the National Cancer Institute</u> , (1999), volume 91(2), pages 143-151.					
	59.	"Combretastatin Update 1: In Ohio Phase 1 Trial, Some Tumors Respond, Patients Experience Vascular Stress"; <u>PSA Rising; Medical Pike Briefs; Headline Index: Clinical Trial Phase 1 Results</u> ; Nov. 8, 1999.					
	60.	Zhou, et al.; "A difference between the rat and mouse in the pharmacokinetic interaction of 5, 6-dimethylxanthene-4-acetic acid with thalidomide"; <u>Cancer Chemother Pharmacol</u> , (2001), 47(6), 541-544.					
EXAMINER					DATE CONSIDERED		
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							
**Copies of references not provided at the time of this submission.							

**RECEIVED**

JAN 28 2003

Page 7 of 15

TECH CENTER 1600/2900


USPTO Form 1449 U.S. Department of Commerce Patent and Trademark Office				Attorney Docket No. 8654/2072		Serial No. 10/014,887	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				Applicant(s): Krissansen, et al.			
				Filing Date: December 11, 2001		Group: 1615	
U.S. PATENT DOCUMENTS							
Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
FOREIGN PATENT DOCUMENTS							
Examiner Initial		Document No.	Publication Date	Country	Class	Subclass	Translation YES NO
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)							
	61.	Zhou, et al.; "Determination of unbound concentration of the novel anti-tumor agent 5, 6-dimethylxanthenone-4-acetic acid in human plasma by ultrafiltration followed by high-performance liquid chromatography with fluorimetric detection"; <u>J. of Chromatography B</u> ; (2001) 757(2), 359-363.					
	62.	Zhou, et al.; "Determination of the covalent adducts of the novel anti-cancer agent 5, 6-dimethylxanthenone-4-acetic acid in biological samples by high-performance liquid chromatography"; <u>J. of Chromatography B</u> ; (2001) 757: 343-348.					
	63.	Zhou, et al.; "Reversible binding of the novel anti-tumor agent 5, 6-dimethylxanthenone-4-acetic acid to plasma proteins and its distribution into blood cells in various species"; <u>J. of Pharmacy and Pharmacology</u> ; (2001) 53(4), 463-471.					
	64.	Zhou, et al.; "In vitro and in vivo kinetic interactions of the antitumour agent 5, 6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenac"; <u>Cancer Chemother. Pharmacol.</u> ; (2001) 47(4), 319-326.					
	65.	Cao, et al.; "Interferon-inducible Protein 10 Induction and Inhibition of Angiogenesis in Vivo by the Antitumor Agent 5, 6-Dimethylxanthenone-4-acetic Acid (DMXAA)"; <u>Cancer Research</u> ; (2001) 61(4), 1517-1521.					
	66.	Murata, et al.; "Comparative effects of combretastatin A-4 disodium phosphate and 5, 6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumor and normal tissues"; <u>Int. J. Radiat. Biol.</u> ; (2001) vol. 77, no. 2, 195-204.					
EXAMINER					DATE CONSIDERED		
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							
**Copies of references not provided at the time of this submission.							

**RECEIVED**

JAN 28 2003

TECH CENTER 1800/2900

USPTO Form 1449 U.S. Department of Commerce Patent and Trademark Office SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				Attorney Docket No. 8654/2072		Serial No. 10/014,887		
				Applicant(s): Krissansen, et al.				
				Filing Date: December 11, 2001		Group: 1615		
U.S. PATENT DOCUMENTS								
Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)	
FOREIGN PATENT DOCUMENTS								
Examiner Initial		Document No.	Publication Date	Country	Class	Subclass	Translation	
							YES	NO
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)								
	67.	Zhou, et al.; "Identification of the Human Liver Cytochrome P450 Isoenzyme Responsible for the 6-Methylhydroxylation of the Novel Anticancer Drug 5, 6-Dimethylxanthenone-4-Acetic Acid"; <u>Drug Metabolism and Disposition</u> , A Publication of The American Soc. for Pharma. and Exper. Therap.; (2000) 28(12) 1449-1456.						
	68.	Siim, et al.; "Scintigraphic Imaging of the Hypoxia Marker ^{99m} Tc-labeled 2, 2'(1,4-Diaminobutane) bis (2-methyl-3-butanone) Dioxime (^{99m} Tc-labeled HL-91; Prognox): Noninvasive Detection of Tumor Response to the Antivascular Agent 5, 6-Dimethylxanthenone-4-acetic Acid"; <u>Cancer Research</u> ; (2000) 60(16), 4582-4588.						
	69.	Aitken, et al.; "Synthesis and Antitumor Activity of New Derivatives of Flavone-8-acetic Acid (FAA), Part 4: Variation of the Basic Structure"; <u>Arch. Pharm. Pharm. Med. Chem.</u> ; (2000) 333(6) 181-188.						
	70.	Zhou, et al.; "Determination of two major metabolites of the novel anti-tumor agent 5, 6-dimethylxanthenone-4-acetic acid in hepatic microsomal incubations by high-performance liquid chromatography with fluorescence detection"; <u>J. of Chromatography B</u> ; (1999) 734(1): 129-136.						
	71.	Ching, et al.; "Induction of STAT and NFkB Activation by the Antitumor Agents 5,6-Dimethylxanthenone-4-acetic Acid and Flavone Acetic Acid in a Murine Macrophage Cell Line"; <u>Biochemical Pharmacology</u> ; (1999) 58(7) 1173-1181.						
EXAMINER					DATE CONSIDERED			
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant. **Copies of references not provided at the time of this submission.</small>								

**RECEIVED**

JAN 28 2003

TECH CENTER 1600/2900USPTO Form 1449 U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket No.

Serial No.

8654/2072

10/014,887

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT**

Applicant(s): Krissansen, et al.

Filing Date: December 11, 2001

Group: 1615

U.S. PATENT DOCUMENTS

Examiner Initial	Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document No.	Publication Date	Country	Class	Subclass	Translation	
						YES	NO


OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

72.	Cao, et al.; "Thalidomide increases both intratumoural tumor necrosis factor- α production and anti-tumor activity in response to 5, 6-dimethylxanthenone-4-acetic acid"; <u>British Journal of Cancer</u> ; (1999) 80(5,6), 716-723.
73.	Kestell, et al.; "Plasma disposition, metabolism and excretion of the experimental antitumour agent 5, 6-dimethylxanthenone-4-acetic acid in the mouse, rat and rabbit"; <u>Cancer Chemother. Pharmacol.</u> ; (1999) 43(4), 323-330.
74.	Joseph, et al.; "Stimulation of Tumors to Synthesize Tumor Necrosis Factor- α in Situ Using 5,6-Dimethylxanthenone-4-acetic Acid: A Novel Approach to Cancer Therapy"; <u>Cancer Res.</u> (1999) 59(3), 633-638.
75.	Wilson, et al.; "Enhancement of Tumor Radiation Response by the Antivascular Agent 5, 6-Dimethylxanthenone-4-Acetic Acid"; <u>Int. J. Radiation Oncology Biol. Phys.</u> ; (1998) Vol. 42 No. 4, 905-908
76.	Zaks-Zilberman, et al; "Induction of Adrenomedullin mRNA and Protein by Lipopolysaccharide and Paclitaxel (Taxol) in Murine Macrophages"; <u>Infection and Immunity</u> ; (1998) 66 (10), 4669-4675.
77.	Pang, et al.; "Antitumour Activity of the Novel Immune Modulator 5, 6-Dimethylxanthenone-4-acetic Acid (DMXAA) in Mice Lacking the Interferon-gamma Receptor"; <u>European Journal of Cancer</u> ; (1998) 34(8): 1282-1289.
78.	Bruce C. Bagule and Lai-Ming Ching; "Immunomodulatory Actions of Xanthenone Anticancer Agents"; <u>BioDrugs</u> ; (1997) 8(2): 119-127.

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

**Copies of references not provided at the time of this submission.

**RECEIVED**

JAN 28 2003

TECH CENTER 1600/2900USPTO Form 1449 U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket No.

Serial No.

8654/2072

10/014,887

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT**

Applicant(s): Krissansen, et al.

Filing Date: December 11, 2001

Group: 1615

U.S. PATENT DOCUMENTS

Examiner Initial	Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document No.	Publication Date	Country	Class	Subclass	Translation	
						YES	NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

	79.	Siim, et al.; "Nitro Reduction as an Electronic Switch for Bioreductive Drug Activation"; <u>Oncology Research</u> ; (1997) 9(6/7), 357-369.
	80	Baguley, et al.; "Increased Plasma Serotonin Following Treatment With Flavone-8-Acetic Acid, 5,6-Dimethylxanthenone-4-Acetic Acid, Vinblastine, and Colchicine: Relation to Vascular Effects"; <u>Oncology Research</u> ; (1997) 9(2), 55-60.
	81.	Moilanen, et al.; "Persistent induction of nitric oxide synthase in tumours from mice treated with the anti-tumor agent 5, 6-dimethylxanthenone-4-acetic acid"; <u>British Journal of Cancer</u> ; (1998) 77(3): 426-433.
	82	Philpott, et al.; "Production of tumor necrosis factor- α by cultured human peripheral blood leukocytes in response to the anti-tumor agent 5, 6-dimethylxanthenone-4-acetic acid (NSC 640488)"; <u>British Journal of Cancer</u> ; (1997) 76(12): 1586-1591.
	83.	Everett, et al.; "High-performance ion chromatography applied to free-radical mechanisms in drug design. The problem of ion analysis at high ionic strengths"; <u>Journal of Chromatography A</u> ; (1997) 770(1,2), 273-279.
	84.	Patel, et al.; "The Effect of 5, 6-Dimethylxanthenone-4-acetic acid on Tumor Necrosis Factor Production by Human Immune Cells"; <u>Anticancer Research</u> (1997) 17(1A), 141-150.
	85.	Vincent, et al.; "Chemotherapy with DMXAA (5, 6-dimethylxanthenone-4-acetic acid) in combination with CI-1010 (1H-imidazole-1-ethanol, α -[[2-bromoethyl]amino]methyl]-2-nitro-, mono-hydrobromide (R isomer)) against advanced stage murine colon carcinoma 26"; <u>Oncology Reports</u> ; (1997) 4(1), 143-147.

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

**Copies of references not provided at the time of this submission.



RECEIVED

JAN 28 2003

USPTO Form 1449 U.S. Department of Commerce Patent and Trademark Office		TECH CENTER 1600/2900		Attorney Docket No. 8654/2072		Serial No. 10/014,887	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				Applicant(s): Krissansen, et al.			
				Filing Date: December 11, 2001		Group: 1615	
U.S. PATENT DOCUMENTS							
Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
FOREIGN PATENT DOCUMENTS							
Examiner Initial		Document No.	Publication Date	Country	Class	Subclass	Translation YES NO
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)							
	86.	Miners, et al.; "Preclinical Prediction of Factors Influencing the Elimination of 5, 6-Dimethylxanthenone-4-acetic Acid, a New Anticancer Drug"; <u>Cancer Research</u> ; (1997) 57(2), 284-289.					
	87.	Watts, et al.; "Changes in coagulation and permeability properties of human endothelial cells in vitro induced by TNF- α or 5, 6 MeXAA"; <u>British Journal of Cancer, Suppl.</u> ; (1996) 74(27): S164-S167.					
	88	Wilson, et al.; "Tertiary amine N-oxides as bioreductive drugs: DACA N-oxide, nitracrine N-oxide and AQ4N"; <u>British Journal of Cancer, Supplemental</u> ; (1996) 74(27), S43-S47.					
	89.	Pedley, et al.; "Ablation of Colorectal Xenografts with Combined Radioimmunotherapy and Tumor Blood Flow-modifying Agents"; <u>Cancer Research</u> ; (1996) 56(14), 3293-3300.					
	90.	William R. Wilson and Frederik B. Pruijn; "Hypoxia-Activated Prodrugs as Antitumour Agents: Strategies for Maximizing Tumor Cell Killing"; <u>Clinical and Experimental Pharmacology and Physiology</u> ; (1995) 22(11), 881-885.					
	91.	Hill, et al.; "Anti-Vascular Approaches to Solid Tumor Therapy: Evaluation of Vinblastine and Flavone Acetic Acid"; <u>Int. J. Cancer</u> ; (1995) 63(1), 119-123.					
	92.	Philpott, et al.; "Induction of tumor necrosis factor- α by single and repeated doses of the antitumour agent 5, 6-dimethylxanthenone-4-acetic acid"; <u>Cancer Chemother. Pharmacol.</u> ; (1995) 36(2) 143-148.					
	93.	Laws, et al.; "Preclinical in vitro and in vivo activity of 5, 6-dimethylxanthenone-4-acetic acid"; <u>British Journal of Cancer</u> ; (1995) 71(6), 1204-1209.					
	94.	Webster, et al.; "Metabolism and Elimination of 5, 6-Dimethylxanthenone-4-Acetic Acid in the Isolated Perfused Rat Liver"; <u>Drug Disposition, A Publication of The Amer. Soc. for Pharm. and Exper. Therapeutics</u> ; (1995) 23(3): 363-368.					
EXAMINER					DATE CONSIDERED		
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							
**Copies of references not provided at the time of this submission.							

**RECEIVED**

JAN 28 2003

TECH CENTER 1800/2900USPTO Form 1449 U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket No.

8654/2072

Serial No.

10/014,887

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT**

Applicant(s): Krissansen, et al.

Filing Date: December 11, 2001

Group: 1615

U.S. PATENT DOCUMENTS

Examiner Initial	Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document No.	Publication Date	Country	Class	Subclass	Translation	
						YES	NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

95.	Perera, et al.; "Activation of LPS-Inducible Genes by the Antitumor Agent 5, 6-Dimethylxanthene-4-Acetic Acid in Primary Murine Macrophages"; <u>The Journal of Immunology</u> ; (1994) 153(10), 4684-4693.
96.	Zwi, et al.; "The Morphological Effects of the Anti-Tumor Agents Flavone Acetic Acid and 5, 6-Dimethyl Xanthene Acetic Acid on the Colon 38 Mouse Tumor"; <u>Pathology</u> ; (1994) 26(2), 161-169.
97.	Kestell, et al.; "Disposition of the novel antitumor agent xanthene-4-acetic acid in the mouse: identification of metabolites and routes of elimination"; <u>Xenobiotica</u> ; (1994) 24(7): 635-647.
98.	Pedley, et al.; "Enhancement of Radioimmunotherapy by Drugs Modifying Tumor Blood Flow in a Colonic Xenograft Model"; <u>Int. J. Cancer</u> ; (1994) 57(6), 830-835.
99.	Everett, et al.; "Decarboxylation of the antitumor drugs flavone-8-acetic acid and xanthene-4-acetic acid by nitrogen dioxide"; <u>Anti-Cancer Drug Design</u> ; (1994) 9(1), 68-72.
100.	Ching, et al.; "Effect of Tumor Growth on the Macrophage Response to the Antitumor Agent 5, 6-Dimethylxanthene-4-acetic Acid"; <u>Anticancer Research</u> ; (1993) 13(6A), 2069-2075.
101.	Ching, et al.; "Induction of Tumor Necrosis Factor- α Messenger RNA in Human and Murine Cells by the Flavone Acetic Acid Analogue 5, 6-Dimethylxanthene-4-acetic"; <u>Cancer Research</u> ; (1994) 54(4), 870-872.
102.	Thomsen, et al.; "Nitric Oxide: its production in host-cell-infiltrated EMT6 spheroids and its role in tumor cell killing by flavone-8-acetic acid and 5, 6-dimethylxanthene-4-acetic acid"; <u>Cancer Chemother. Pharmacol.</u> ; (1992) 31(2), 151-155.
103.	Veszelszky, et al.; "Flavone Acetic Acid and 5, 6-Dimethylxanthene-4-acetic Acid: Relationship between Plasma Nitrate Elevation and the Induction of Tumor Necrosis"; <u>Eur. J. Cancer, Part A</u> ; (1993) 29A(3): 404-408.

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

**Copies of references not provided at the time of this submission.

**RECEIVED**

JAN 28 2003

TECH CENTER 1600/2900

USPTO Form 1449 U.S. Department of Commerce Patent and Trademark Office				Attorney Docket No. 8654/2072		Serial No. 10/014,887	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				Applicant(s): Krissansen, et al.			
				Filing Date: December 11, 2001		Group: 1615	
U.S. PATENT DOCUMENTS							
Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
FOREIGN PATENT DOCUMENTS							
Examiner Initial		Document No.	Publication Date	Country	Class	Subclass	Translation YES NO
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)							
	104.	Gamage, et al.; "Structure-activity relationship for substituted 9-oxo-9, 10-dihydroacridine-4-acetic acids: analogues of the colon tumor active agent xanthenone-4-acetic acid"; <u>Anti-Cancer Drug Design</u> ; (1992) 7(5), 403-414.					
	105.	Ching, et al.; "Antitumour responses to flavone-8-acetic acid and 5, 6-dimethylxanthenone-4-acetic acid in immune deficient mice"; <u>Br. J. Cancer</u> ; (1992); 66(1), 128-130.					
	106.	Ching, et al.; "Stimulation of macrophage tumouricidal activity by 5, 6-dimethylxanthenone-4-acetic acid, a potent analogue of the antitumour agent flavone-8-acetic acid"; <u>Biochemical Pharmacology</u> ; (1992) 44(1): 192-195.					
	107.	Thomsen, et al.; "Modulation of superoxide production from murine macrophages by the antitumour agent flavone acetic acid and xanthenone acetic acid analogues"; <u>Biochemical Pharmacology</u> ; (1992); 43(2): 386-389.					
	108.	Ching, et al.; "In vitro Methods for Screening Agents with an Indirect Mechanism of Antitumour Activity: Xanthenone Analogues of Flavone Acetic Acid"; <u>Eur. J. Cancer</u> ; (1991); 27(12) 1684-1689.					
	109.	Ching, et al.; "Haematological effects in mice of the antitumour agents xanthenone-4-acetic acid, 5, 6-dimethylxanthenone-4-acetic acid and flavoneacetic acid"; <u>Cancer Chemother. Pharmacol.</u> ; (1991) 28(6), 414-419.					
	110.	McKeage, et al.; "Plasma pharmacokinetics of the antitumour agents 5, 6-dimethylxanthenone-4-acetic acid, xanthenone-4-acetic acid and flavone-8-acetic acid in mice"; <u>Cancer Chemother. Pharmacol.</u> ; (1991) 28(6), 409-413.					
EXAMINER					DATE CONSIDERED		
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							
**Copies of references not provided at the time of this submission.							

RECEIVED

JAN 28 2003

TECH CENTER 1600/2900

JAN 27 2003

USPTO Form 1449 U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket No.

Serial No.

8654/2072

10/014,887

SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT

Applicant(s): Krissansen, et al.

Filing Date: December 11, 2001

Group: 1615

U.S. PATENT DOCUMENTS

Examiner Initial	Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document No.	Publication Date	Country	Class	Subclass	Translation	
						YES	NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)


	111.	Rewcastle, et al.; "Potential Antitumor Agents. 63. Structure-Activity Relationships for Side-Chain Analogues of the Colon 38 Active Agent 9-oxo-9H-xanthenone-4-acetic Acid"; <u>J. Med. Chem.</u> ; (1991) 34(9), 2864-2870.
	112.	Zwi, et al.; "Necrosis in non-tumor tissues caused by flavone acetic acid and 5, 6-dimethyl xanthenone acetic acid"; <u>Br. J. Cancer</u> ; (1990) 62(6), 932-934.
	113.	Ching, et al.; "Induction of Natural Killer Activity by Xanthenone Analogues of Flavone Acetic Acid: Relation with Antitumour Activity"; <u>Eur. J. Cancer</u> ; (1991); 27(1) 79-83.
	114.	Kestell, et al.; "Determination of xanthenone-4-acetic acid in mouse plasma by high-performance liquid chromatography"; <u>J. of Chromatography</u> ; (1991) 564(1), 315-321.
	115.	Thomsen, et al.; "Evidence for the Production of Nitric Oxide by Activated Macrophages Treated with the Antitumor Agents Flavone-8-acetic Acid and Xanthenone-4-acetic Acid"; <u>Cancer Research</u> ; (1990); 50(21), 6966-6970.
	116.	Rewcastle, et al.; "Potential Antitumor Agents. 61. Structure-Activity Relationships for in Vivo Colon 38 Activity among Disubstituted 9-oxo-9H-xanthenone-4-acetic Acids"; <u>J. Med. Chem.</u> ; (1991); 34(1), 217-222.
	117.	Rewcastle, Gordon W.; "Synthesis and Development of Two New Classes of Anticancer Drugs: the tricyclic Carboxamides and the xanthenoneacetic acids"; <u>Chemistry in New Zealand</u> ; (1989); 53(6): 145-150.
	118.	Rewcastle, et al.; "Light-Induced Breakdown of Flavoneacetic Acid and Xanthenone Analogues in Solution"; <u>J. Natl. Cancer Inst.</u> ; (1990); 82(6): 528-529.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

**Copies of references not provided at the time of this submission.

**RECEIVED**

JAN 28 2003

USPTO Form 1449 U.S. Department of Commerce
Patent and Trademark Office

TECH CENTER 1600/2900

Attorney Docket No.

8654/2072

Serial No.

10/014,887

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT**

Applicant(s): Krissansen, et al.

Filing Date: December 11, 2001

Group: 1615

U.S. PATENT DOCUMENTS

Examiner Initial	Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document No.	Publication Date	Country	Class	Subclass	Translation	
						YES	NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

	119.	Atwell, et al.; "Synthesis and anti-tumor activity of topologically-related analogues of flavoneacetic acid"; <u>Anti-Cancer Drug Design</u> ; (1989); 4(2) 161-169.
	120.	Van der Auwera, et al.; "Conformational Features of Four Model Tripeptides Having Piv-Pro-MeXaa-Nme ₂ Sequences"; <u>Bull. Soc. Chim. Belg.</u> ; (1988) 97(3): 199-207.

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

**Copies of references not provided at the time of this submission.